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BACKGROUND: We reported recently the clinical efficiency of interferon (IFN)-a/5-fluorouracil (5-FU) combination therapy in advanced
hepatocellular carcinoma (HCC). However, prediction of the response to the combination therapy remains unsatisfactory. The aim of
this study was to investigate the anti-tumour effects of microRNA (miR)-21 on the sensitivity of HCC cells to IFN-a/5-FU and
whether miR-21 can be used as a predictor of the response to such therapy in HCC.
METHODS: Changes in the sensitivity of HCC cells (PLC/PRF/5 and HepG2) to IFN-a/5-FU were examined after transfection with
pre-miR-21 or anti-miR-21. The correlation between miR-21 expression level, evaluated by qRT–PCR, and response to the therapy
was also investigated in clinical HCC specimens.
RESULTS: Hepatocellular carcinoma cells transfected with pre-miR-21 were significantly resistant to IFN-a/5-FU. Annexin V assay
showed that the percentage of apoptotic cells was significantly lower in cells transfected with pre-miR-21 than control cells.
Transfection of anti-miR-21 rendered HCC cells sensitive to IFN-a/5-FU, and such sensitivity was weakened by transfection of
siRNAs of target molecules, PETN and PDCD4. miR-21 expression in clinical HCC specimens was significantly associated with the
clinical response to the IFN-a/5-FU combination therapy and survival rate.
CONCLUSIONS: The miR-21 in HCC cell lines and clinical HCC samples is a significant modulator of the anti-tumour effect of IFN-a and
5-FU. This suggests that miR-21 is a potentially suitable marker for the prediction of the clinical response to the IFN-a/5-FU
combination therapy.
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Hepatocellular carcinoma (HCC) is one of the most common
malignancies worldwide. The prognosis of patients with advanced
HCC remains poor, particularly in patients with tumour thrombi
in the major trunk of the portal vein (Tanaka et al, 1996; Asahara
et al, 1999). In such patients, conventional therapies have no
clinical impact because of poor efficacy and possible complications
(Furuse et al, 1997; Lee et al, 1997). Accordingly, new therapeutic
approaches are needed for patients with advanced HCC.
Several studies have reported encouraging results for the
therapeutic effects of the interferon (IFN)-based combination
chemotherapy in HCC, compared with unsatisfactory results of
IFN-a monotherapy (Urabe et al, 1998; Chung et al, 2000; Patt
et al, 2003; Obi et al, 2006; Uka et al, 2007; Ueshima et al, 2008).
We have also reported the clinical efficiency of IFN-a and
5-fluorouracil (5-FU) (IFN-a/5-FU) combination therapy for
advanced HCC and the mechanism of its anti-tumour effect (Eguchi
et al, 2000; Sakon et al,2 0 0 2 ;Y a m a m o t oet al, 2004; Kondo et al,
2005; Ota et al, 2005; Nakamura et al, 2007; Wada et al, 2007, 2009;
Damdinsuren et al,2 0 0 7 a , b ;N a g a n oet al, 2007a,b; Noda et al,
2009). These studies showed that IFN-a suppresses the proli-
feration of all type I IFN receptor type 2 (IFNAR2)-positive cancer
cell lines in vitro, and that the expression of IFNAR2 in HCC tissues
was significantly associated with clinical response to the IFN-a/5-FU
combination therapy. These results indicate that IFNAR2 expression
might be useful in the prediction of the clinical response to the
combination therapy (Ota et al, 2005; Nagano et al, 2007a).
However, the same studies also included several patients who were
positive for IFNAR2 expression but did not show good clinical
response, suggesting that the clinical response to the therapy cannot
be predicted satisfactorily only by the expression of IFNAR2 (Ota
et al, 2005; Nagano et al, 2007a). Accordingly, it is necessary to find
novel biological markers that can more accurately predict the
clinical response to the IFN-a/5-FU therapy.
MicroRNA (miR) is a small noncoding RNA gene product
known to modulate the gene expression post-transcriptionally by
negatively regulating the stability or translational efficiency of its
target mRNAs (Bartel, 2004; Calin and Croce, 2006a). miRs control
a wide array of biological processes, including cell differentiation,
proliferation, and apoptosis. Aberrant expression of miRs has
been widely reported in human cancers with both up- and
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sdownregulation detected in neoplastic cells compared with their
normal counterparts (Croce and Calin, 2005; Calin and Croce,
2006b). Recently, some investigators reported a correlation
between miRs expression and chemoresistance in several types
of cancers. For example, Fujita et al (2008) reported that the
expression of miR-34a attenuated chemoresistance to an anti-
cancer drug in prostate cancer cells. Furthermore, the expression
of miR-122 was also reported to be significantly associated with the
sensitivity to sorafenib and doxorubicin (Bai et al, 2009; Fornari
et al, 2009). Among these previous reports of correlation of miRs
expression to chemoresistance, miR-21, which is reported to be
increased in many cancers including HCC, is one of the most
common miRs related to chemoresistance (Volinia et al, 2006;
Meng et al, 2007). For example, it was reported that the miR-21
reduced the sensitivity to gemcitabine in cholangiocarcinoma
cells (Meng et al, 2006). Also in glioblastoma cells, the miR-21
is reported to contribute to VM-26 resistance (Li et al, 2009).
Furthermore, several studies reported a significant association
between miR-21 expression and chemoresistance to gemcitabine in
pancreatic cancer cells (Moriyama et al, 2009; Park et al, 2009).
In this study, we first examined the effects of miR-21 expres-
sion level in HCC cell lines on their sensitivity to IFN-a and 5-FU, and
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Figure 1 The expression level of miR-21 in five HCC cell lines including
PLC/PRF/5, HuH7, HLE, HLF, and HepG2, and clinical samples from
30 patients with advanced HCC. The miR-21 expression was normalised by
the average expression in non-tumoural tissues. The expression in tumoural
tissue was significantly higher than in non-tumoural tissue (*Po0.05). Data are
mean±s.d. T ¼tumoural tissue; N¼ non-tumoural tissue.
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Figure 2 Transfection of pre-miR-21 into PLC/PRF/5 and HepG2. (A) qRT–PCR showed significant overexpression of miR-21 in the transfected cells compared
with control cells (*Po0.05). (B) MTT assay showed that the anti-tumour effects of the combination of IFN-a and 5-FU in the miR-21 upregulated cells was significantly
lower than in control cells (*Po0.05). (C and D)M T Ta s s a yr e v e a l e dt h a tt h ea n t i - t u m o u re f f e c t so fI F N - a (C)a n d5 - F U( D) in the miR-21 upregulated cells was
significantly less profound than in control cells (*Po0.05). (E) The percentage of early apoptotic cells induced by 1000IU per ml IFN-a or 1.0mgp e rm l5 - F Ua m o n g
miR-21 upregulated cells was significantly lower than in control cells (*Po0.05). Data are mean±s.d. of three experiments.
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sconfirmed that miR-21 induced resistance to these chemotherapeutic
agents. In the second part of the study, the expression level of miR-21
in human HCC tissue samples was significantly associated with the
clinical response to the IFN-a/5-FU combination therapy.
MATERIALS AND METHODS
HCC cell line
The human HCC cell lines, PLC/PRF/5, HuH7, HLE, HLF, and
HepG2, were obtained from the Japan Cancer Research Resources
Bank (Tokyo, Japan). They were maintained in Dulbecco’s modi-
fied Eagle’s medium supplemented with 10% fetal bovine serum,
100U per ml penicillin and 100mg per ml streptomycin at 371Ci n
a humidified incubator with 5% CO2 in air.
Drugs and reagents
Purified human IFN-a and 5-FU were kindly supplied by Otsuka
Pharmaceutical Co. (Tokyo, Japan) and Kyowa Hakko Kirin Co.
(Tokyo, Japan), respectively. Monoclonal mouse anti-human
phosphatase and tensin homologue (PTEN) antibody (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) and polyclonal rabbit
anti-human programmed cell death 4 (PDCD4) antibody (Abcam
Inc., Cambridge, MA, USA) were used for western blot analysis and
immunohistochemistry.
Transfection
microRNA-21 precursor (pre-miR-21), antisense miR-21 inhibitor
(anti-miR-21), PTEN siRNA, PDCD4 siRNA, and their negative
control oligonucleotides were obtained from Ambion Inc. (Austin,
TX, USA). These were used to transfect HCC cells by using siPORT
NeoFx (Ambion Inc.) according to the instructions provided by
the manufacturer. The transected cells were resuspended and
cultured in regular culture medium for 48–72h before analysis.
Patients and specimens
The study subjects were 30 patients with advanced HCC and
recruited as described previously (Nagano et al, 2007a). All
patients had multiple liver tumours in both lobes and tumour
thrombi in the main trunk of the portal vein, and each underwent
palliative reduction surgery with tumour thrombectomy of the
main trunk of the portal vein at the Osaka University Hospital
between 1999 and 2004. The IFN-a/5-FU therapy for the remnant
multiple liver tumour was applied postoperatively, as described
previously (Ota et al, 2005; Nagano et al, 2007a). Patients were
followed after surgery with postoperative follow-up period of
18.2±19.7 months (mean±s.d.). The clinical response to the
therapy was evaluated according to the criteria of the Eastern
Cooperative Oncology Group (Oken et al, 1982). On the basis of
the clinical response, responders were defined as patients with
complete response or partial response, and non-responders were
defined as patients with stable disease or progressive disease. The
study protocol was approved by the Human Ethics Review
Committee of Osaka University Hospital and a signed consent
form was obtained from each patient.
RNA extraction
Total RNA and miR fractions were isolated from tissue samples
and cell lines by TRIzol agent (Invitrogen, Carlsbad, CA, USA), and
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sthe quality of the RNA was assessed with a NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington,
DE, USA) at 260 and 280nm (A260/280).
Real-time quantitative reverse transcription-PCR for miR
expression
Reverse transcription (RT) reaction and real-time quantitative
RT-PCR (qRT–PCR) were performed using Taqman human miR
assay kit (Applied Biosystems, Foster City, CA, USA) according to
the instructions supplied by the manufacturer. The expression of
the target miR was normalised relative to that of the internal
control, RNU48. Data were analysed according to the comparative
Ct method (Schmittgen et al, 2004).
Real-time qRT-PCR for mRNA expression
Reverse transcription reaction was performed with SuperScript II
(Invitrogen) on the basis of the protocol provided by the manu-
facturer, and qRT–PCR was performed as described previously
(Kondo et al, 2005). The expression of the target gene was
normalised relative to the expression of porphobilinogen deami-
nase (PBGD), which was used as an internal control. The designed
PCR primers were as follows: matrix metalloproteinase (MMP)-2
forward primer, 50-TGGCGATGGATACCCCTTT-30; MMP-2
reverse primer, 50-TTCTCCCAAGGTCCATAGCTCAT-30; MMP-9
forward primer, 50-CCTGGGCAGATTCCAAACCT-30; MMP-9
reverse primer, 50-GCAAGTCTTCCGAGTAGTTTTGGAT-30; MMP-11
forward primer, 50-TGACTTCTTTGGCTGTGCC-30 MMP-11
reverse primer, 50-GTTGTCATGGTGGTTGTACCC-30; PBGD forward
primer, 50-TGTCTGGTAACGGCAATGCGGCTGCAAC-30; PBGD re-
verse primer, 50-TCAATGTTGCCACCACACTGTCCGTCT-30.
Western blot analysis
Cells grown to semiconfluence were lysed in RIPA buffer (25mM
Tris (pH 7.5), 50mM NaCl, 0.5% sodium deoxycholate, 2% Nonidet
P-40, 0.2% sodium dodecyl sulphate, 1mM phenylmethylsulphonyl
fluoride and 500KIE per ml Trasylol, proteinase inhibitor (Bayer,
LeverKusen, Germany)). Western blot analysis was carried out as
described previously (Kondo et al, 2005).
Growth-inhibitory assay
Inhibition of cell growth in the presence of chemotherapeutic
agents was assessed by the 3-(4-,5-dimethylthiazol-2-yl)-2,
5-diphenyl tetrazolium bromide (MTT) (Sigma-Aldrich Co.,
St Louis, MO, USA) assay as described previously (Eguchi et al,
2000). Briefly, the cells were incubated for 72h under various
concentrations of IFN-a and 5-FU. After re-incubation for 4h with
MTT solution, acid-isopropanol was added to dissolve the
resultant formazan crystals. The absorbance of the plate was
measured in a microplate reader at a wavelength of 570nm with a
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s650nm reference, and the results were expressed as the percentage
of absorbance relative to untreated controls.
Annexin V assay
The binding of Annexin V was used as a sensitive method for
measuring apoptosis, as described previously (Nakamura et al,
2007). At 24h after treatment, cells were stained by Annexin
V-FITC and propidium iodide (PI) (BioVision Research Products,
Mountain View, CA, USA), and analysed on a FACS Calibur
(BD Biosciences, Franklin Lakes, NJ, USA). Annexin V-positive
and PI-negative cells considered as early apoptotic cells were used
for the assessment of apoptosis in the study (Lugli et al, 2005).
Immunohistochemistry
Immunohistochemical staining for PTEN and PDCD4 in the
above-mentioned 30 HCC samples was performed by the method
described previously (Kondo et al, 2005). Briefly, after deparaffi-
nisation and blocking, the sections were incubated overnight at
41C with the antibody. The sections were counterstained with
Meyer’s haematoxylin. The PTEN and PDCD4 expression, defined
as the presence of specific staining in the cytoplasm of cancer cells,
was evaluated as positive or negative.
Statistical analysis
Data were expressed as mean±s.d. Clinicopathological parameters
were compared using the w
2-test, and continuous variables were
compared using the Student’s t-test. Survival curves were
computed using the Kaplan–Meier method, and differences
between survival curves were compared using the log-rank test.
A P-value less than 0.05 denoted the presence of a statistically
significant difference. Statistical analysis was performed using
StatView (version 5.0, SAS Institute Inc., Cary, NC, USA).
RESULTS
microRNA-21 expression is upregulated in tumoural tissue
compared with non-tumoural tissue in HCC patients
The expression of miR-21 was examined in tumoural tissue
and non-tumoural tissue of the 30 patients with advanced HCC
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Figure 4 Transfection of anti-miR-21 into PLC/PRF/5 and HepG2. (A) The suppression of miR-21 in the transfected cells was confirmed by qRT–PCR
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profound than in control cells (*Po0.05). (C and D) MTT assay showed significantly more anti-tumour effects of IFN-a (C) and 5-FU (D) on the viability of
the miR-21 downregulated cells than in control cells (*Po0.05). (E) Annexin V assay showed that the percentage of early apoptotic cells induced by
1000IU per ml IFN-a or 1.0mg per ml 5-FU was significantly higher in the miR-21 downregulated cells than in control cells (*Po0.05). Data are mean±s.d.
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sand also in the HCC cell lines. The expression in tumoural
tissue was significantly higher compared with non-tumoural
tissue, as reported previously by Meng et al (2007) (Po0.0001)
(Figure 1). The expression in the HCC cell lines varied as shown
in Figure 1.
Transfection of pre-miR-21 induces resistance to IFN-a
and 5-FU
To evaluate the effect of miR-21 on the response to IFN-a and
5-FU, we transfected pre-miR-21 into PLC/PRF/5 and HepG2,
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swhich showed the highest and lowest expression level of miR-21
among the five cell lines, respectively. The expression of miR-21
was confirmed to be significantly increased in the transfected
cells by qRT–PCR (Figure 2A). The MTT assay showed that
cells overexpressing miR-21 were significantly more resistant to
the combination therapy of IFN-a and 5-FU than the control
cells (Figure 2B). Next, we investigated the effect of transfection of
pre-miR-21 on the separate growth-inhibitory effect of each of
IFN-a and 5-FU. The result showed that transfection of pre-miR-21
significantly weakened the growth-inhibitory effect of both IFN-a
and 5-FU in the two cancer cell lines compared with the control
cells (Figure 2C and D). We also evaluated the extent of apo-
ptosis of these cells at 24h induced by treatment with 1000IU
per ml IFN-a or 1.0mg per ml 5-FU by the Annexin V assay. The
percentage of early apoptotic cells was significantly lower in the
two cancer cell lines transfected with pre-miR-21 than in control
cells (Figure 2E).
Next, the expression levels of PTEN and PDCD4, representing
the target molecules of miR-21, were examined by western blot
analysis. The expression of these molecules was significantly
suppressed in the pre-miR-21-transfected cells (Figure 3A). In
addition, the expression levels of MMP-2, MMP-9, and MMP-11,
which are also mediated by miR-21, were assessed by qRT–PCR.
The results indicated that miR-21 positively modulated the mRNA
expression of these MMPs (Figure 3B).
Transfection of anti-miR-21 induces sensitivity to
IFN-a and 5-FU
To further assess the effect of miR-21, we transfected anti-miR-21
into PLC/PRF/5 and HepG2. Transfection of cells with anti-miR-21
suppressed miR-21 level compared with the control cells
(Figure 4A). The MTT assay showed that the miR-21-suppressed
cells were significantly more sensitive to the combination therapy
of IFN-a and 5-FU than control cells (Figure 4B). Furthermore, the
growth-inhibitory effect of a single agent (IFN-a or 5-FU) was
significantly enhanced in the two cancer cell lines transfected with
anti-miR-21 compared with the control cells (Figure 4C and D). In
other experiments, Annexin V assay showed significant increase in
the percentages of apoptosis of anti-miR-21-transfected cells
treated with 1000IU per ml IFN-a or 1.0mg per ml 5-FU than
control cells (Figure 4E).
PTEN and PDCD4 are responsible for the miR-21-induced
resistance
We next sought to identify the target molecule responsible for
the miR-21-induced resistance. As a potential target molecule,
we focused on PTEN and PDCD4, which were confirmed as target
molecules by the aforementioned results and also reported
previously to be related to apoptosis and drug sensitivity (Jansen
et al, 2004; Yu et al, 2008; Vaidya et al, 2009; Li et al, 2010).
Downregulation of PTEN and PDCD4 expression by their
respective siRNAs, PLC/PRF/5, and HepG2 cells became more
resistant to the combination therapy (10IU per ml IFN-a and
0.5mg per ml 5-FU) (Figure 5). In addition, the enhanced growth-
inhibitory effect by the aforementioned anti-miR-21 transfection
was weakened after the addition of PTEN or PDCD4 siRNA
(Figure 5). These findings suggest that PTEN and PDCD4 are
responsible, at least in part, for the miR-21-induced resistance.
MiR-21 expression is associated with clinical response to
the IFN-a/5-FU combination therapy and prognosis
Next, we examined the relation between miR-21 expression in
tumoural tissue and clinical response to the IFN-a/5-FU combina-
tion therapy. The expression levels of miR-21 in the tumoural
tissue varied widely among the patients (Figure 1). A total of
15 patients with values more than the median miR-21 expression
level were assigned to the miR-21 high-expression group and the
remaining 15 patients were assigned to the miR-21 low-expression
group. The clinicopathological factors related to the miR-21
expression status are summarised in Table 1. The data indicate
that miR-21 expression did not correlate with any of the clinico-
pathological factors. We also evaluated the correlation between
miR-21 expression level and clinical response to the IFN-a/5-FU
combination therapy. As shown in Table 2, 13.3% (2/15) of
patients of the miR-21 high-expression group were evaluated as
responders to the IFN-a/5-FU therapy, compared with 53.3%
(8/15) of the miR-21 low-expression group, suggesting that the
miR-21 expression was significantly associated with the clinical
response to the IFN-a/5-FU combination therapy (P¼0.0201). In
other words, miR-21 expression was significantly higher in non-
responders than in responders (P¼0.0109, Figure 6A). The
sensitivity, specificity, and accuracy for the prediction of the
response to IFN-a/5-FU therapy by miR-21 expression were 80.0%
(8/10), 65.0% (13/20), and 70.0% (21/30), respectively.
Next, we examined PTEN and PDCD4 expression by immuno-
histochemistry using clinical specimens from the 30 patients.
Staining for PTEN and PDCD4 was noted in the cytoplasm of
tumour cells of samples of 8 and 11 patients, respectively
(Figure 6B). Although there was no significant association between
PTEN expression and miR-21 expression, the expression of PDCD4
tended to correlate with that of miR-21 (Table 3). Neither PTEN
nor PDCD4 expression was significantly associated with the
response to the IFN-a/5-FU combination therapy (Table 3). These
results suggest that analysis of miR-21 expression is more useful
for predicting the response to the combination therapy than that of
the two representative target molecules, PTEN and PDCD4.
Finally, we examined the relationship between miR-21 expres-
sion and prognosis. The overall survival rate of the miR-21
low-expression group was significantly better than that of the miR-
21 high-expression group (P¼0.0250, Figure 6C). These results
suggest that miR-21 expression in HCC tissues is a useful marker
for prediction of the clinical response to the combination therapy
and prognosis.
Table 1 Correlation between clinicopathological factors and miR-21
expression status
miR-21 expression
High
(n¼15)
Low
(n¼15) P-value
Age (years)
a 54.2±9.3 58.1±13.4 0.3669
Gender (male/female) 13/2 14/1 40.9999
Child-Pugh classification (A/B) 9/6 10/5 0.7048
AFP (ngml
 1)( o400/X400) 5/10 6/9 0.7048
PIVKA-II (mAUl
 1)( o1000/X1000) 1/14 5/10 0.1686
Histological grade (mod/poor/
undifferentiated)
0/14/1 1/12/2 0.4754
IFNAR2 status (±) 5/10 5/10 40.9999
Abbreviations: AFP¼a-fetoprotein; IFNAR2¼type I interferon receptor type 2;
miR¼microRNA; mod¼moderately differentiated; PIVKA-II¼protein induced by
vitamin K absence or antagonists-II; poor¼poorly differentiated.
aData are
mean±s.d.
Table 2 Association between miR-21 expression and clinical response
to the combination therapy
Responders Non-responders P-value
miR-21 high expression (n¼15) 2 13 0.0201
miR-21 low expression (n¼15) 8 7
Abbreviation: miR¼microRNA.
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sDISCUSSION
In this study, we analysed the expression of miR-21 in HCC cell
lines and clinical HCC samples. Previously, Meng et al (Meng et al,
2007) reported a significantly high expression of miR-21 in HCC
cells and that miR-21 contributed to cell proliferation, migration,
and invasion. Although we did not examine migration or invasion
of HCC cells transfected with miR-21, we confirmed signifi-
cant increase in proliferation of cells transfected with miR-21
compared with control cells (data not shown), in agreement with
the previous report of Meng et al (2007). To our knowledge,
however, there are no reports on the correlation between miR-21
expression and chemoresistance in HCC. In this study, we
found a significant relationship between miR-21 expression and
chemoresistance in HCC.
Several investigators have reported the correlation of
miR-21 expression with chemoresistance in pancreatic cancer,
cholangiocarcinoma, and glioblastoma (Meng et al, 2006;
Li et al, 2009; Moriyama et al, 2009; Park et al, 2009). The result
of this study that miR-21 expression was associated with chemo-
resistance in HCC was consistent with these previous reports.
However, few of the above reports examined the underlying
mechanism of the miR-21-induced chemoresistance. In the
majority of the above reports on miR-21-induced chemoresistance,
miR-21 induced changes in the expression of target molecules
deemed potentially responsible for the chemoresistance. However,
these studies did not evaluate the change in chemoresponsiveness
after manipulation of the expression of the target molecules. For
example, Meng et al (2007) reported that miR-21 inhibited
gemcitabine-induced apoptosis by negatively regulating PTEN
and its downstream pathway, based on previous reports of
the association between PTEN expression and chemosensitivity
(Yu et al, 2008; Vaidya et al, 2009). Other studies reported miR-21-
induced chemoresistance by downregulation of PDCD4 proteins,
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Figure 6 Expression of the miR-21 and its target molecules, PTEN and PDCD4, in tumoural tissue, and the clinical response to the IFN-a/5-FU
combination therapy in clinical HCC samples. (A) The expression of miR-21 in non-responders was significantly higher than in responders (*Po0.05). Data
are mean±s.d. (B) Representative cases of PTEN-positive (upper left) or negative (upper right) and PDCD4-positive (lower left) or negative (lower right)
(Bar¼200mm) tumours. The expression was identified in the cytoplasm of tumour cells in the positive cases. (C) Postoperative overall survival was
significantly better in the miR-21 low-expression group than in the miR-21 high-expression group (*Po0.05). T¼tumour lesion (arrowheads); N¼non-
tumour lesion.
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son the basis of previous reports of the relation between PDCD4
and chemosensitivity (Jansen et al, 2004; Bourguignon et al, 2009).
Moriyama et al (2009) also reported miR-21 induced chemoresis-
tance to gemcitabine and changes in MMPs expression, and
speculated that these miR-21-induced changes in chemoresistance
were mediated through MMPs, based on previous reports that the
miR-21 indirectly induced MMPs expression (by negative regula-
tion of tissue inhibitor of metalloproteinases 3 (TIMP3) and
reversion-inducing cysteine-rich protein with Kazal motifs
(RECK)) and that MMPs levels correlated significantly with
chemosensitivity (Gabriely et al, 2008; Almendro et al, 2009; Song
et al, 2009). On the other hand, in addition to the confirmation of
miR-21-induced chemoresistance and changes in the aforemen-
tioned target molecules in pre-miR-21-transfected cells including
PTEN, PDCD4, and MMPs, we also demonstrated that the miR-21-
induced changes in chemoresponse were ameliorated by down-
regulation of PTEN or PDCD4 by the respective siRNA. Thus, our
results suggest that miR-21 induces chemoresistance to IFN-a and
5-FU, mediated through PETN and PDCD4. Furthermore, we
also confirmed the association between miR-21 expression and
response to the combination therapy in clinical HCC samples. Our
analysis demonstrated that miR-21 expression, but not PTEN or
PDCD4, correlated significantly with the response to the combina-
tion therapy. It was noteworthy that the expression levels of PTEN
and PDCD4 tended to correlate inversely with that of miR-21 in
tumour tissues. This discrepancy suggests that the expression of
both PTEN and PDCD4 is under the control of not only miR-21 but
also their mRNAs and/or those of various posttranslational
modulators including other miRs. In general, miRs modulate the
expression of multiple target molecules, suggesting there are
possibly other unknown target molecules of miR-21 responsible
for the chemoresistance other than PTEN and PDCD4. Taken
together, determination of miR-21 expression rather than various
target molecules provides a better prediction of the response to the
combination therapy.
We reported previously that IFNAR2 and epithelial cell adhesion
molecule (EpCAM) correlate significantly with the clinical
response to the IFN-a/5-FU combination therapy (Ota et al,
2005; Nagano et al, 2007a; Noda et al, 2009). Therefore, in this
study, we investigated the effects of pre-miR-21 transfection on the
expression status of IFNAR2 and EpCAM. The result showed no
significant change in the expression status (data not shown),
suggesting that the chemoresistance induced by miR-21 is different
from the relationship between the anti-tumour effect and IFNAR2
and EpCAM expression.
In summary, the results of this study demonstrated a significant
association between the miR-21 expression and the response to
IFN-a and 5-FU in HCC cell lines in genetic manipulation
experiments. Moreover, this significant correlation was also
confirmed in human clinical HCC samples. Our findings suggest
that the miR-21 could be a potentially useful marker for the
prediction of the clinical response to the IFN-a/5-FU combination
therapy, and that the miR-21 may serve as a potential target for
HCC therapy.
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